Stress-Induced Th2 Shift Thyroid Autoimmunity

Stress-Induced Th2 Shift and Thyroid Autoimmunity: A Unifying Hypothesis

Stress-Induced Th2 Shift – Thyroid Autoimmunity

Thyroid autoimmunity may manifest clinically as chronic autoimmune or Hashimoto’s thyroiditis (HT) and its variants (postpartum/sporadic thyroiditis) or as Graves’ disease (GD) and atrophic thyroiditis. These autoimmune thyroid diseases (AITD) occur as a result of aberrant immune response against thyroid antigens due to breakdown of self-tolerance [1]. Although HT and GD share a common genetic background and may occur in the same family or the same individual, they have different pathophysiology and clinical presentation. Evidence suggests that the phenotypic presentation of AITD as GD or HT largely depends on the predominant pattern of immune response during the development of autoimmunity. This is likely determined by environmental factors, through epigenetic effects, among which stress appears to play an important role [2,3]. Stress affects the immune system through activation of neuroendocrine pathways. During a stress response the hypothalamic-pituitary-adrenal (HPA) axis and the sympathetic nervous system (SNS) are activated, resulting in systemic elevations of glucocorticoids and catecholamines. These neuroendocrine responses are essential for the organism in maintaining homeostasis [4].

It has long been thought that stress hormones, glucocorticoids in particular, exert a generalized immune suppressive effect. However, accumulating evidence suggests that stress, through its effector neuroendocrine pathways, has a differential effect on the immune response, suppressing cellular and potentiating humoral immunity [5,6]. This review supports the hypothesis that stress, by affecting the balance of immune response, may influence the clinical expression of thyroid autoimmunity.

Regulation of Th1 and Th2 immune responses

The pattern of immune response (cellular vs. humoral) is largely regulated by antigen-presenting cells (APCs) such as dendritic cells (DCs), macrophages and natural killer (NK) cells, which are components of innate immunity. APCs’ major function is to present non-self antigens in conjunction with major histocompatibility complex (MHC) molecules and co-stimulatory signals to CD4+ T helper (Th) cells. Depending on the signal they receive from APCs, naive CD4+ Th cells are further differentiated into Th1 or Th2 cells that are components of adaptive immunity. In turn, Th1 cells secrete pro-inflammatory (type 1) cytokines, including interferon (INF)-gamma, interleukin (IL)-2 and tumor necrosis factor (TNF)-alpha, which are responsible for cell-mediated immune responses. On the other hand, Th2 cells produce anti-inflammatory (type 2) cytokines, primarily IL-4, IL-5, IL-10 and IL-13, which provide help to antigen specific B lymphocytes to produce antibodies involved in humoral immunity [7,8]. A third member of the T helper cell class, IL-17 producing CD4+ T cells, called Th17 cells has been recently recognized as a distinct Th subset, and has been linked to autoimmune inflammatory disorders.

Recent studies on the Th1/Th2 paradigm helped in better understanding of the mechanisms of differentiation of each subset as well as the transcription factors involved in their regulation. Thus, evidence suggests that IL-12 is important for Th1-cell differentiation, through STAT4 (signal transducer and activator of transcription 4) and the activation of the transcription factor T-bet (T-box expressed T cells), which upregulates INF-gamma and other type 1 cytokines and downregulate the expression of type 2 cytokines. Conversely, IL-4 induces Th2-cell differentiation through STAT6 and activation of GATA3 transcription factor, which upregulates IL-4 and IL-5 and downregulates INF-gamma expression [9,10], (Figure 1).

Stress-Induced Th2 Shift and Thyroid Autoimmunity Figure 1

Figure 1. Interleukin (IL)-12 and IL-4 direct the differentiation of naïve CD4+ T cells towards Th1 or Th2 subtypes producing type 1 or type 2 cytokines, respectively. Th2 cells express the transcription factor GATA-3 that induces expression of Th2- specific cytokines and inhibits IFN-gamma production in developing Th1 cells. T-bet, a Th1-speciffic T-box transcription factor, induces IFN-gamma and represses IL-4 and IL-5 production in Th2 cells.

Stress hormones and the Th1/Th2 balance

Effect of glucocorticoids and catecholamines

Evidence suggests that glucocorticoids, at levels achieved during stress, suppress cell-mediated and potentiate humoral immunity. Glucocorticoids, acting through their cytoplasmic/nuclear receptors on APCs, suppress the production of IL-12, the main cytokine inducer of Th1 responses, and downregulate the expression of IL-12 receptors on T cells and natural killer cells, thus inhibiting INF-gamma production. On the other hand, glucocorticoids promote the production of IL-4 and IL-10 by the Th2 cells. The latter could be the result of diminishing the restraining effect of IL-12 and INF-gamma on Th2 cells [11 – 14]. Additional evidence suggests that glucocorticoids may also block the transcriptional activity of T-bet, the key transcription factor in Th1-mediated cellular immunity [15].

In a similar way, catecholamines, acting on APCs through beta2-adrenergic receptors (ARs) suppress the production of IL-12, thus inhibiting the differentiation of Th1 cells, while enhancing Th2 cell differentiation [16]. Furthermore, catecholamines appear to inhibit the production of TNF-alpha and potentiate the production of IL-10 by APCs [17,18]. Notably, beta2-ARs are expressed only on Th1 and not on Th2 cells, and this may provide an additional explanation for the differential effect of catecholamines on Th1/Th2 balance. Thus, beta2-AR agonists inhibit INF-gamma production by Th1 cells but do not affect IL-4 production by Th2 cells [19]. Furthermore, glucocorticoids can enhance the sensitivity of peripheral mononuclear cells to the immunomodulatory effects of catecholamines, indicating cooperative effects of the stress hormones on the immune deviation of the type1/type2 cytokine balance in favor of type 2 expression [20]. In conclusion, main stress hormones, glucocorticoids and catecholamines appear to cause selective suppression of cellular immunity and enhance humoral immunity by down-regulating type-1 and up-regulating type-2 cytokine expression.

Epigenetic regulation of T cell differentiation and stress hormones

Epigenetic regulation of gene expression is an important mechanism that controls transcriptional activation or repression of specific gene loci. Methylation of CpGs DNA is generally associated with transcriptional inactivity within a gene locus, whereas removal of the methyl group from cytosine signals a shift from inert chromatin to active or open loci [21].

Recent studies have examined and implicated DNA methylation as a significant regulator of lineage commitment and specific cytokine production during Th cell differentiation [22]. Mice deficient of a maintenance methyltransferase (Dnmt 1) experience ectopic cytokine production in T cells, where aberrant expression of IL-4  is attributed to inappropriate demethylation and  depressed silencing of the IL-4  gene [23].

The differentiation of naive CD4+ T lymphocytes along the Th1 or Th2 differentiation pathway is thought to be regulated by epigenetic mechanisms leading to activation or silencing of the locus encoding type 2 cytokines (IL-4, IL-13) or the locus encoding IFN-gamma, respectively [24]. A general model proposes that naive T cells have the potential to differentiate into either Th1 or Th2 cells. Following induction of the differentiation program, the transcriptional rate of IL-4 and IFN-gamma genes diverge. The Th1 differentiation program leads to increase in the transcriptional activity of IFN-gamma gene and the silencing of the genes for IL-4, IL-5 and IL-13. The opposite is true for the Th2 differentiation program, which leads to increased transcriptional activity of IL-4, IL-5 and IL-13 genes and silencing of the INF-gamma gene. Key stimulators of the Th1 differentiation program include IL-12 and the transcription factor STAT4 and the IFN-gamma/STAT1-transcription factor T-bet signaling pathways, whereas stimulators of the Th2 differentiation program includes the IL-4/STAT6 and the transcription factor GATA-3 signaling pathway [25].

It appears that specific epigenetic changes regulate the activation of INF-gamma gene during the process of differentiation of CD4+ T cells into Th1 cells and also the silencing of the same gene in differentiating Th2 cells [24]. Recent evidence suggests that specific histone-methylation patterns of chromatin surrounding INF-gamma gene could explain the permissive chromatin environment for INF-gamma gene expression in differentiated Th1 cells, relative to the non-permissive chromatin environment for IFN-gamma gene expression in Th2 cells [26]. The dynamic nature of the epigenetic changes that drive the silencing of IFN-gamma gene is dependent on two transcriptional activators of Th2 cell differentiation:  GATA3 and STAT 6. In Th1 cells, the histone-acetylation across the INF-gamma gene locus is dependent on STAT 4 and T-bet [27]. Glucocorticoid hormones bind to glucocorticoid receptors, which act as transcription regulators of many genes. Among these genes, of particular interest is DNA (cytokine-5)-methytransferase 1 (Dnmt1). Dnmt1 is involved in preservation of DNA methylation pattern as well as in de novo DNA methylation, and is important in epigenetic transcription repression [28]. Recent reports suggest that glucocorticoids can modulate Dnmt 1 expression [29]. There is also experimental evidence suggesting that the activated glucocorticoid receptor inhibits T-bet by direct protein-protein interaction and that glucocorticoid treatment reduces T-bet and STAT1 expression in mononuclear cells [15,30].

It is likely, therefore, that stress hormones, glucocorticoids in particular may influence T cell differentiation towards a Th2-type response, through epigenetic modification. The exact mechanism involved in this process awaits further elucidation.

The Th1/Th2 balance in thyroid autoimmunity

AITD, the most common-organ-specific autoimmune condition, may present clinically either as HT and its variants (postpartum or sporadic thyroiditis), or as GD, and atrophic thyroiditis [31]. The main autoantigens in AITD are thyroglobulin (TG), thyroid peroxidase (TPO) and the TSH receptor (TSHr). HT is characterized by lymphocytic infiltration of the thyroid parenchyma causing a diffuse or micronodular goitre in association with positive serum anti-TPO and/or anti-TG antibodies, and varying degrees of thyroid dysfunction. The intra-thyroidal immune cells are T and B lymphocytes with CD4+ Th1–subtype predominating, although Th2 cells are also present [32]. Thyroid follicular cells in close proximity to the infiltrating lymphocytes appear apoptotic, suggesting immune-mediated apoptotic destruction of these cells [33].

On the other hand, in GD, there is a follicular cell hypertrophy and hyperplasia along with hyperfunction, manifesting as a diffuse goitre and hyperthyroidism. The lymphocytic infiltration of the thyroid is patchy and not as massive as in HT and the majority of T lymphocytes are CD4+ Th2 cells, although Th1 cell are also present. TSHr-stimulating antibodies are the hallmark of Graves disease, and are responsible for the thyroid follicular growth and hyperfunction [32,34]. On the other hand, atrophic thyroiditis is rare and is characterized by a small (atrophic) thyroid gland and clinical hypothyroidism. TSHr-blocking antibodies are present in up to 50% of patients with atrophic thyroiditis and may be responsible for thyroid atrophy and hypofunction [35].

Studies in animal models suggest that thyroid autoimmunity is a three-stage process [43]. In the first stage, there is an increase of intra-thyroidal APC’s which take up and present thyroid auto-antigens together with MHC class II antigens plus co-stimulatory molecules to the CD4+T cells. The second stage involves the interaction of the Th lymphocytes with the presented autoantigen. If immune tolerance and its regulation by co-stimulatory signals are lost, then inappropriate activation of antigen-specific T-lymphocytes takes place, leading to differentiation and clonal expansion of autoreactive CD4+ Th cells, and antibody-producing B lymphocytes. In the final stage, the generated autoreactive T and B lymphocytes accumulate in large numbers within the thyroid parenchyma, which becomes “a battlefield” with infiltrating lymphocytes and defending thyreocytes. The outcome of this interaction is largely dependent on the Th1/Th2 balance and the pattern of cytokines released in the local microenvironment [1,2], and determines the clinical phenotypes of thyroid autoimmunity.

Predominance of a Th1-type immune response, favoring cell-mediated immunity, may create a pro-apoptotic milieu for the thyroid cells. Fas and/or TNF-related apoptosis-inducing ligand (TRAIL)-dependent apoptotic pathways are activated by type-1 proinflammatory cytokines such as TNF-alpha, INF-gamma and IL-2, and the thyroid cells undergo apoptosis, leading to HT or its variants [37,38]. A predominant Th2–type immune response, favoring humoral immunity, may induce antigen-specific B lymphocytes to produce anti-TSHr antibodies. If the prevailing type of anti-TSHr antibodies is stimulatory, thyroid cell hyperplasia and hyperfunction ensue, leading to Graves’ hyperthyroidism. If, on the other hand, TSHr blocking antibodies predominate, then thyroid cell atrophy and hypofunction occur, leading to atrophic thyroiditis (Figure 2).

stress Th2 shift thyroid autoimmunity

Figure 2. Role of Th1/Th2 balance in the regulation of thyroid autoimmunity and the phenotypic expression of autoimmune thyroid disease.

Thus, the phenotypic expression of thyroid autoimmunity towards GD or HT is dependent on the balance of Th1 vs. Th2 immune responses regulated by APCs and the type of cytokines predominating in the thyroid parenchyma. The fact that both conditions may develop in the same individual at different time points, suggests that the Th1/Th2 balance is a dynamic process that may be influenced by exogenous factors acting on APCs.

Association of stress with thyroid autoimmunity

The first clinical observation of an association between stressful life events and hyperthyroidism was made by Parry in 1825 along with the description of the disease, and subsequently by Graves, von Basedow and others [39]. Both physical stress, such as trauma or major illness, and psychological stress such as bereavement have been implicated. These early reports were followed by epidemiological observations of an increased incidence of hyperthyroidism during major wars, a condition named “kriegsbasedow” [40]. Thus, the incidence of hyperthyroidism in the Danish population increased significantly during the 1941-1945 German occupation. Also, Hospital admissions for thyrotoxicosis in occupied Scandinavian countries increased five- to six-fold during the 1939-1945 war and returned to normal rates after the war [40].

More recent evidence for such an association was the five-fold increase in GD compared to toxic nodular goitre (TNG) observed during the civil war in former Yugoslavia [41]. Other studies failed to show an increase in antithyroid drug use during the civil unrest in Northern Ireland [42] or an increase in preceding stressful life events in thyrotoxic patients attending an outpatient’s clinic [43]. However, the latter reports failed to distinguish between GD and other causes of thyrotoxicosis. In an earlier study, Forteza found that most of his 115 patients experienced stressful events just before the first signs of GD [44].

Following these early clinical observations, a number of case-control studies and population-based surveys using self-rated questionnaires have examined the effect of stress on the onset or the clinical course of Graves’ thyrotoxicosis.

Stress and the onset of Graves’ disease

The first large population-based clinical study that established an association between stressful life events and the onset of GD was from Sweden. Using a self-rated questionnaire, 208 patients with newly diagnosed GD were found to have more negative life events and higher negative life event scores in the year preceding the diagnosis, compared to 372 controls [45]. Subsequent case-control studies in different ethnic populations, confirmed the association of stressful life events with the onset of GD [46-48]. One of these studies from Japan reported an association of stress with GD in women but not in men [49].

The above studies have been criticized because of their retrospective nature, the influence of recall bias, and the fact that thyrotoxicosis itself might also manifest with anxiety symptoms and negative emotional events, raising the question of distinguishing between cause and effect [50,51]. This problem was partially addressed by a more recent study that compared patients with GD to patients with TNG and healthy controls, in order to correct for the effect of thyrotoxicosis. A significant increase in the number of negative life events was found in the GD patients compared to those with TNG and normal controls [52]. This finding supports the notion that stress may precipitate autoimmune as opposed to non-autoimmune hyperthyroidism. A recent nested case-control study in a cohort of 790 euthyroid women, who were first and second degree relatives of AITD patients, examined prospectively the relationship between stress and the de novo occurrence of thyroid antibodies or the development of clinical autoimmune hyper-/hypothyroidism. The authors reported that exposure to stress was not different between subjects who developed TPO-Abs and those who did not. Also no differences were observed in stress exposure between hyper-/hypothyroid cases and controls. Based on these findings, the authors concluded that, stress is not involved in the pathogenesis of AITD [53].

Stress and the clinical course of Graves’ disease

Few studies have examined the effect of stress on the clinical course of GD. In a retrospective study, treatment with a benzodiazepine, in addition to routine antithyroid drug therapy, reduced the relapse rate of thyrotoxicosis from 74% in patients not treated with benzodiazeoine to 29% in those treated with benzodiazepine, suggesting that stress management was effective in improving the prognosis of GD [54]. Two prospective case-control studies also suggest that stress may have a negative impact on the outcome of GD. The first study from Japan investigated the outcome of patients with newly diagnosed GD after 12 months antithyroid drug therapy in relation to stressful life events. The authors reported that “daily stresses “at 6 months after starting therapy were associated with continued hyperthyroid state 12 months later [55]. This effect was seen only in women, however, as the number of males in the study was too small to reach a significant effect. In a more recent study, it was shown that the relapse rate after antithyroid drug treatment for GD was related to daily stresses and some personality traits, and that stress scores correlated with the level of anti-TSHr antibodies after cessation of antithyroid drugs [56]. The findings from these studies, although limited in number, indicate that stress may affect the clinical course of GD.

Several case reports also support a relationship between stress and the onset or outcome of GD. Misaki et al. reported three cases of Graves’ hyperthyroidism occurring after partial thyroidectomy for papillary carcinoma [57]. The authors suggested that surgical stress might alter immune homeostasis converting preclinical into clinical Graves’ hyperthyroidism. An association of stress with the onset and clinical course of GD has also been reported in children. Mortillo and Gardner describe four children in whom a “separation” event was related to the onset or relapse of GD [58]. We have reported five patients who developed mild autoimmune hyperthyroidism following a major stressful life event such as bereavement, job loss, stress at work, and major surgery. In all cases, the hyperthyroidism went into a remission following a short course (up to 6 months) of a low dose antithyroid drug treatment, and resolution of the stress situation [59].

Stress and Hashimoto’s thyroiditis

In contrast to GD, few studies have examined the association between stress and HT. Two case-control studies evaluated the role of stressful events in HT or postpartum thyroiditis. They concluded that stress was not the trigger in either condition [60,61]. A recent population study also did not find a relationship between stressful life events and the presence of anti-TPO antibodies among euthyroid women [62].The onset and clinical course of HT are often insidious and the diagnosis may be delayed until the patient develop overt hypothyroidism, making it difficult to assess the role of stress in the onset and natural history of the disease.

In summary, the evidence from the available epidemiological observations and clinical studies suggests a possible association between stress and GD but not with HT. The biological mechanisms underlying the association of stress with GD are not known, but a possible explanation is given below.

Stress in the clinical expression of thyroid autoimmunity: a unifying hypothesis

Evidence from animal studies and clinical observations suggests that a hyperactive or hypoactive stress response may be associated with decreased or increased vulnerability to different types of autoimmune diseases [63]. For example, Fisher rats, that have hyperactive stress system, are resistant to experimentally induced Th1-mediated autoimmune diseases, such as rheumatoid arthritis, uveitis, and experimental allergic encephalomyelitis. Conversely, Lewis rats, which have hypoactive HPA axis, are prone to develop Th1-mediated autoimmune conditions [64].

A physiological condition with changing in the Th1/Th2 balance is pregnancy and the postpartum period. Pregnancy causes suppression of Th1-mediated cellular immune activity and preservation or enhancement of Th2-mediated humoral immunity. In the third trimester, Th1-type cytokines such as INF-gamma and IL-2 decline and Th2 cytokines, in particular IL-4, increase. This shift may permit the histoincompatible fetal-placental unit to avoid rejection by a cell-mediated maternal immune attack [64,65]. These immune changes in pregnancy develop in parallel with a marked increase in glucocorticoids along with increases in estrogen and progesterone. Progesterone appears to cause a shift in the Th1/Th2 balance similar to that described for glucocorticoids [66]. Indeed, the changes in the hormonal milieu may explain why pregnant women experience remission of Th1-mediated autoimmune disease such as rheumatoid arthritis, multiple sclerosis, and autoimmune thyroiditis, and aggravation of Th2-mediated autoimmune conditions such as lupus erythematosus [67-69].

In the postpartum period, the hormonal milieu changes abruptly, with glucocorticoids, estrogens and progesterone decreasing to subnormal levels, allowing a prompt recovery of cell-mediated immune function [68]. This Th2 to Th1 “return shift” might explain the increase in the incidence of postpartum thyroiditis and other Th1-mediated autoimmune conditions. Analogous clinical situations associated with a decreased stress system activity are seen during the period that follows cure from Cushing’s syndrome or discontinuation of glucocorticoid therapy [70-71]. These situations have been associated with increased susceptibility to Th1-mediated immune disorders. A similar rebound reaction may occur in periods that follow cessation of chronic stress. Conversely, GD and other Th2-predominant conditions are frequently associated with allergic diseases [72]. Further support for the importance of the Th2 pathway in GD comes from observations that recurrence after anti-thyroid drug therapy is more likely following an attack of allergic rhinitis with elevated lgE levels, which is a marker of Th2 activity [73]. Interestingly, in this regard, humanized anti-CD52 monoclonal antibody therapy for multiple sclerosis, that causes change in the immune response from Th1 to Th2 phenotype, was reported to trigger the development of GD [74].

On the basis of these observations and the information cited above, a unifying hypothesis for the role of stress in the clinical expression of AITD can be formulated. Environmental factors, interacting with genetic factors, may induce an aberrant immune response against thyroid autoantigens and render an individual susceptible to develop thyroid autoimmunity. The potential of precursor CD4+T lymphocytes to differentiate toward Th1 or Th2 type activity following interaction with APCs is an important switching point for the development of cell-mediated versus humoral autoimmunity. If a susceptible individual is under severe stress, the stress hormones may steer the balance toward a Th2 phenotype. Effector Th2 cells and type 2 cytokines will then induce antigen-specific B lymphocytes to produce anti-TSHr antibodies. The concomitant suppression of Th1-effector pathway will protect thyroid cells from a cell-mediated immune attack. Under these circumstances, the clinical outcome will be GD. Conversely, if a susceptible person is recovering from a stress response (when the stress axis is hypoactive) or postpartum, when  the immune suppressive effect of pregnancy is gone, a rebound reaction may reactivate the Th1-mediated branch pathway, leading to cellular immune response and apoptotic destruction of thyroid follicular cells by the proinflammatory cytokines. The likely outcome will then be autoimmune (sporadic) or postpartum thyroiditis, respectively (Figure 3).

stress Th2 shift

Figure 3. Role of stress in the clinical expression of thyroid autoimmunity.


Circumstantial evidence suggests that HT and GD, the two opposite clinical entities of AITD, manifest different immune phenotypes. HT is predominately a Th1-mediated autoimmune disease, whereas GD has a predominant Th2 phenotype. There is convincing evidence from epidemiological and clinical studies supporting the hypothesis that stress may favor the development of GD, but there is limited information on the role of stress in HT. However, whether stress plays a causative role in the development of GD is not yet clear.

It is likely, that in susceptible individuals, stress hormones may influence the clinical expression of thyroid autoimmunity towards the development of GD by suppressing cellular immunity and potentiating humoral immunity. Epigenetic mechanisms may be involved in this process. On the other hand, recovery from stress, though a rebound effect of cellular immunity, may favor the development of autoimmune thyroiditis. This is a working hypothesis based on circumstantial evidence and needs further substantiation. Future studies also need to focus on identifying agents that can restore the type1/type2 cytokine balance, in the presence of stress hormones, and serve as a basis for the interventions to prevent the stress-associated immune conditions in humans.

Author(s) Affiliation

A Tsatsoulis, C Limniati – Department of Endocrinology, University of Ioannina 45110, Ioannina Greece

Corresponding author: Agathocles Tsatsoulis, MD, PhD, FRCP; Professor of Medicine-Endocrinology, Department of Endocrinology, University of Ioannina, 45110, Ioannina, Greece;  Email:

  1. Weetman AP (2004) Cellular immune responses in autoimmune thyroid disease. Clinical Endocrinology 61, 405-413
  2. Fountoulakis S, Tsatsoulis A. (2004) On the pathogenesis of autoimmune thyroid disease: a unifying hypothesis. Clinical Endocrinology 60, 379-409
  3. Prummel MF, Stieder T, Wiersinga WM. (2004). The environment and autoimmune thyroid diseases. European Journal of Endocrinology 150, 605-618
  4. Chroussos GP. (1998). Stressors, stress and neuroendocrine integration of the adaptive response. The 1997 Hans Selye memorial lecture. Annals of New York  Academy of Sciences 851, 311-315
  5. Elenkov IJ, Chroussos GP. (1999) Stress hormones, Th1/Th2 patterns, pro/anti-inflammatory cytokines and susceptibility to disease. Trends in Endocrinology and Metabolism. 13, 567-581
  6. Rook GAW. (1999) Glucocorticoids and immune function. Bailliere’s Clinical Endocrinology and Metabolism, 13, 567-581
  7. Abbas AK, Murphy WKM, Sher A. (1996) Functional diversity of helper T-lemphocytes. Nature 383, 787-795
  8. Fearon DT, Locksley RM (1996). The instructive role of innate immunity in the acquired immune response. Science 272, 50-53
  9. Murphy KM, Renier SL.(2002) The lineage decisions of helper T cells. Nature Reviews in Immunology 2, 935-944
  10. Szabo SJ, Sullivan BM, Peng SL, Glimcher LH. (2003) Molecular mechanisms regulating Th1 immune responses. Annual Reviews in Immunology 21, 713-758
  11. Blotta MH, Rekruyff RH, Umetsu DJ. (1997) Corticosteroids inhibit IL-12 production in human monocytes and enhance their capacity to induce IL-4 synthesis in CD4+ lymphocytes. Journal of Immunology 158, 5589-5595
  12. Wu CY, Wang JF, Dyer MC, Seder RA. (1998) Prostaglandin E2 and dexamethasone inhibit IL-12 receptor expression and IL-12 responsiveness. Journal of Immunology 161, 2733-2730
  13. Ramivez F, Fowell BJ, Puklavec M, Simmonds S, Masom D. (1990) Glucocorticoids promote a Th2 cytokine response by CD4+ T cells in vitro. Journal of Immunology 156, 2406-2412
  14. Agarwal SK, Marsall GD. (2001) Dexamethasone promotes type 2 cytokine production primary through inhibition of type 1 cytokines. Journal of Interferon and Cytokine Research 21, 147-155
  15. Liberman AC, Refojo O, Druker J et al. (2007) The activated glucocorticoid receptor inhibits the transcription factor T-bet by direct protein interaction. The FASEB Journal 21, 1177-1188
  16. Elenkov IJ, Papanikolaou DA, Wilder RL, Chrousos GP. (1996) Modulatory effects of glucocorticoids and catecholamines in human interleukin-12 and interleukin-10 production: clinical implications. Proceedings of the Association of American Physicians 108, 374-381
  17. Panina–Bordignon P, Mazzed D, Lucia PD, et al. (1997) Beta2-agonists prevent Th1 development by selective inhibition of interleukin-12. Journal of Clinical Investigation 100, 1513-1519
  18. Agarwal SK, Marsall GD. (2000) Beta-Adrenergic modulation of human type 1/type 2 cytokine balance. Journal of Allergy and Clinical Immunology 105, 91-98
  19. Sanders VM, Baker RA, Ramer-Quinn DS et al (1997). Differential expression of beta2-adrenergic receptor by Th1 and Th2 clones: implications for cytokine production and B-cell help. Journal of Immunology 158, 4200-4210
  20. Salicru AN, Sams CF, Marshall GT. (2007) Cooperative effects of corticosteroids and catecholamines upon immune deviation of the type-1/type-2 cytokine balance in favor of type-2 expression in human peripheral blood mononuclear cells. Brain, Behavior and Immunity 21, 913-920
  21. Ng H-N, Bird A. (1999) DNA methylation and chromatin modification. Current Oppinon in Genetics and Development 9, 158-163
  22. Lee GR, Kim ST, Spilianakis CG, Fields PE, Flavel. RA. (2006) T helper cell differentiation: regulation by cis elements and epigenetics. Immunity 24, 369-379
  23. Lee PP, Fitzpatrick DR, Beard L et al. (2001) A critical role of Dnmt 1 and DNA methylation on T cell development, function and survival. Immunity 15, 763-774
  24. Spilianakis CG, Flavell RA. (2007) Epigenetic regulation of Ifng expression Nature Immunology 8, 681-683
  25. Ansel KM, Lee DU, Rao A. (2003) An epigenetic view of helper T cell differentiation. Nature Immunology 4, 616-623
  26. Schoenborn JR, Dorschner MO, Sekimata M, et al. (2007) Comprehensive epigenetic profiling identifies multiple distal regulatory elements directing transcription of the gene encoding interferon-gamma. Nature Immunology 8, 732-742
  27. Chang S, Aune TM. (2007) Dynamic changes in histone-methylation “marks” across the locus encoding interferon-gamma during the differentiation of T helper type 2 cells. Nature Immunology 8, 723-731
  28. Goyal R, Reinhhardt R, Teltsch A. (2006) Accuracy of DNA methylation pattern preservation by the Dnmt 1 methyltransferase. Nucleic Acids, Research 34, 1182-1182
  29. Ichinose M, Miki K, Tatematsu M et al. (1990) Hydrocortisone induced enhancement of expression and changes in methylation of pepsinogen genes in stomach mucosa of the developing rat. Biochemical and Biophysical Research Communications 172, 1086-1093
  30. Frisullo G, Nociti V, Lorio R et al. (2007) Glucocorticoid treatment reduces T-bet and pSTAT1 expression in mononuclear cells from relapsing remitting multiple sclerosis patients. Clinical Immunology 124, 284-293
  31. Pearce EN, Farwell AP, Braverman LE. (2003) Current concepts: thyroiditis. New England Journal of Medicine 348, 2640-2655
  32. Roura-Mir C, Catalf M, Sospedra M et al. (1997) Single-cell analysis of intrathyroidal lymphocytes shows differential cytokine expression in Hashimoto’s and Graves’ disease. European Journal of Endocrinology 271, 3290-3302
  33. Kotani T, Aratake Y, Hiral K et al.(1995) Apoptosis in thyroid tissue from patients with Hashimoto’s thyroiditis. Autoimmunity 20, 231-236
  34. Hauer M, Aust G, Ode-Haim S, Scherbaum WA. (1990) Different cytokine mRNA profile in Graves’ disease, Hashimoto’s thyroiditis and in immune thyroid disorders determined by quantitative reverse transcriptase polymerase chain reaction (RT-PCR). Thyroid 6, 97-105
  35. Orgiazzi J. (2000) Anti-TSH receptor antibodies in clinical practice. Endocrinology and Metabolism Clinics of North America 29, 339-355
  36. Ruwhof C, Drexhage HA. (2001) Iodine and thyroid autoimmune disease in animal models. Thyroid 11, 427-436
  37. Bretz JD, Baker JR. (2001) Apoptosis and autoimmune thyroid disease : following a TRAIL to thyroid destruction? Clinical Endocrinology 55, 1-11
  38. Andrikoula M, Tsatsoulis A. (2001) The role of Fas-mediated apoptosis in thyroid disease. European Journal of Endocrinology 144, 561-568
  39. Rosch PJ. (1993) Stressful life events and Graves’ disease. Lancet 341, 566-567
  40. Gorman CA. (1990) Environment and Autoimmunity: a critical review of the role of stress in hyperthyroidism in: Drexhage HA, de Vijlder JMM and Wiersinga WM (eds) The Thyroid Gland, Elsenier Science Publishers, Amsterdam, PP.191-200
  41. Paunkovic N, Paunkovic J, Paulovic O, Paunkovic Z. (1998) The significant increase in incidence of Graves’ disease in eastern Servia during the civil war in the former Yugoslavia (1999 to 1995). Thyroid 8, 37-41
  42. Hadden DR, Mc Devitt DG. (1974) Environmental stress and thyrotoxicosis: absence of association. Lancet ii, 577-578
  43. Gray J, Hofenberg R. (1985) Thyrotoxicosis and stress. Quartely Journal of Medicine 54, 153-160
  44. Forteza ME. (1973) Precipitating factors in hyperthyroidism. Geriatrics 28, 123-126
  45. Winsa B, Adami H, Berqstrom R et al. (1991) Stressful life events and Graves’ disease. Lancet 338, 1475-1478
  46. Sovino N, Girelli ME, Boscato M et al. (1993) Life events in the pathogenesis of Graves’ disease. A controlled study. Acta Endocrinologica 128, 293-296
  47. Kung AW. (1995) Life events, daily stresses and coping in patients with Graves’ disease. Clinical Endocrinology 42, 303-308
  48. Rudosavljevic VR, Jancovic SM, Marinkovic JM. (1996) Stressful life events in the pathogenesis of Graves’ disease. European Journal of Endocrinology 134, 699,701
  49. Yoshiuchi K, Kumano H, Nomura S et al. (1998) Stressful life events and smoking were associated with Graves’ disease in women, but not in men. Psychosomatic Medicine 60, 182-185
  50. Chiovato L, Pinchera A. (1996) ) Stressful life events and Graves’ disease. European Journal of Endocrinology 134, 680-682
  51. Dayan CM (2001) Stressful life events and Graves’ disease revisited. Clinical Endocrinology 55, 13-14
  52. Matos-Santos A, Nobile EL, Costa JGE (2001) Relationship between the number and impact of stressful life events and the onset of Graves’ disease and toxic nodular goitre. Clinical Endocrinology 55,15-19
  53. Effraimidis G, Tijssen JGP, Brosschot GF, Wiersinga WM. (2012) Involment of stress in the pathogenesis of autoimmune thyroid disease : a prospective study Pshychoneuroendocrinology 37, 1191-1198
  54. Benvenga S (1996) Benzodiazepines and remission of Graves’ disease. Thyroid 6, 659-600
  55. Yoshiuchi K, Kumaro H, Nomura S et al (1998) Phychosocial factors influence the short-term outcome of antithyroid drug therapy in Graves’ disease. Psychosomatic Medicine 60, 592-596
  56. Fukao A, Takamatsu J, Marakami JY et al (2001) The relationship of psychological factors to the prognosis of hyperthyroidism in antithyroid drug-treated patients with Graves’ disease. Clinical Endocrinology 58, 550-555
  57. Misaki I, Iwata M, Kasagi K et al (2000) Hyperthyroid Graves’ disease after hemithyroidectomy for papillary carcinoma: report of three cases. Endocrine Journal 47, 191-195
  58. Morillo E, Gardner LI.(1979) Bereavement as an antecedent factor in thyrotoxicosis of childhood: four case studies with survey of possible metabolic pathways. Psychosomatic Medicine 41, 545-555
  59. Tsatsoulis A, Panteli K. (1996) Stress-induced mild thyrotoxicosis. European Journal of Internal Medicine 7, 247-250
  60. Martin-du Pan RC. (1998) Triggering role of stress and pregnancy in the occurrence of 98 cases of Graves’ disease compared to 95 cases of Hashimoto’s thyroiditis and 97 cases of thyroid nodules. Annals of Endocrinology (Paris) 59, 107-112
  61. Oretti RC, Harris B, Lazaros JH. (2002) Is there an association between life event, postnatal depression and thyroid dysfunction in thyroid antibody positive women? International Journal of Social Psychiatry 49, 70-76
  62. Streder IGA, Prummel MF, Tussen JGP et al (2005) Stress is not associated with thyroid peroxidase autoantibodies in euthyroid women. Brain Behaviour and Immunity 19, 2003-2006
  63. Wilder RC (1995) Neuroendocrine-immune system interaction and autoimmunity. Annual Reviews in Immunology 83,2003-2006
  64. Elenkov IJ, Hoffman J, Wilder RC. (1997) Does differential neuroendocrine control of cytokine production governs the expression of autoimmune diseases in pregnancy and the post partum period? Molecular Medicine Today 3, 379-383
  65. Raghupathy R. (1997) Th1-type immunity is incompatible with successful pregnancy. Immunology Today 18, 478-482
  66. Miyaura H, Iwata M. (2002) Direct and indirect inhibition of Th1 development by progesterone and glucocorticoids. The Journal of Immunology 168, 1087-1094
  67. Muller AF, Drexhage HA, Berghout A. (2001) Postpartum thyroiditis and autoimmune thyroiditis in women of childbearing age : recent insights and consequences for antenatal and postnatal care. Endocrine Reviews 22, 605-630
  68. Davies TF. (1999) The thyroid immunology in postpartum period. Thyroid 9, 675-684
  69. Hall R. (1995) Pregnancy and autoimmune endocrine disease. Baillieres Clinical Endocrinology and Metabolism 9, 137-155
  70. Takasu N, Komiya I, Nugasawa Y, Asawd T, Yamada T. (1990) Exacerbetion of autoimmune thyroid dysfunction after unilateral adrenalectomy in patients with Cushing’s Syndrome due to an adrenocortical carcinoma. The New England Journal of Medicine 322, 1708-1712
  71. Takasu N, Ohara N, Yamada T, Komiya I. (1993) Development of autoimmune thyroid dysfunction after unilateral adrenalectomy in a patient with Carney’s complex and after removal of ACTH producing adenoma in a patient with Cushing’s disease. Journal Endocrinology Investigation 16, 691-702
  72. Amino N, Hidaka Y, Takano T et al (2003) Association of seasonal allergic rhinitis is high in Graves’ disease and low in painless thyroiditis. Thyroid 13, 811-814
  73. Sato A, Takemura Y, Tamata T et al. (1999) A possible role of immunoglobulin E in patients with hyperthyroid Graves’ disease. Journal of Clinical Endocrinology and Metabolism 84, 3601-3605
  74. Coles AJ, Wing M, Smith S et al. (1999) Pulsed monoclonal antibody treatment and autoimmune thyroid disease in multiple sclerosis. Lancet 354, 1961-1965

    Related stories you may like: Caleb Parry Hyperthyroidism and Stress
    Thyroid Hormone Modulation of Immune Responses in Physiologic and Stressful Conditions:  
    Stress & Organ Specific Autoimmunity 
    Th22 Cells May Contribute To the Pathogenesis of Graves’ Disease
    Th17 Cells Contribute to Hashimoto’s Thyroiditis
    2017 in Review: New Advances in Neuroendocrine Immunology